CARLSBAD, Calif., May 21 /PRNewswire-FirstCall/ — Isis
Pharmaceuticals, Inc. (Nasdaq: ISIS), the leader in antisense therapeutics,
today announced that management will present a company overview at
Citi Investment Research’s 2010 Global Health Care Conference on
Thursday, May 27, 2010 at 2:30 p.m. ET at the New York Hilton
A live audio webcast of the presentation will be available on
the “Investors & Media” section of the Company’s Web site, www.isispharm.com. A
replay of the presentation will be available on the Isis Web site
within 48 hours and will be archived for a limited time.
ABOUT ISIS PHARMACEUTICALS, INC.
Isis is exploiting its expertise in RNA to discover and develop
novel drugs for its product pipeline and for its partners.
The Company has successfully commercialized the world’s first
antisense drug and has 22 drugs in development. Isis’ drug
development programs are focused on treating cardiovascular,
metabolic, and severe neurodegenerative diseases and cancer.
Isis’ partners are developing antisense drugs invented by
Isis to treat a wide variety of diseases. Isis and Alnylam
Pharmaceuticals are joint owners of Regulus Therapeutics Inc., a
company focused on the discovery, development and commercialization
of microRNA therapeutics. Isis also has made significant
innovations beyond human therapeutics resulting in products that
other companies, inclu